Kadmon (KDMN) Rating Lowered to Hold at Zacks Investment Research

Kadmon (NYSE:KDMN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

Other analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a research note on Friday, December 15th. WBB Securities downgraded Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a research note on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Kadmon currently has an average rating of “Hold” and a consensus target price of $8.65.

Shares of Kadmon (NYSE:KDMN) traded up $0.11 during trading on Tuesday, reaching $4.49. The company’s stock had a trading volume of 1,484,400 shares, compared to its average volume of 1,666,582. The company has a market cap of $344.46, a P/E ratio of -2.57 and a beta of 2.54. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.02.

Kadmon (NYSE:KDMN) last announced its earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $5.69 million. Kadmon’s quarterly revenue was down 60.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($4.24) earnings per share. equities research analysts predict that Kadmon will post -1.61 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in shares of Kadmon during the 2nd quarter valued at $114,000. Bank of New York Mellon Corp acquired a new position in shares of Kadmon during the 3rd quarter valued at $119,000. Old West Investment Management LLC acquired a new position in shares of Kadmon during the 3rd quarter valued at $169,000. Wells Fargo & Company MN increased its position in shares of Kadmon by 17.0% during the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after purchasing an additional 8,742 shares during the period. Finally, AE Wealth Management LLC increased its position in shares of Kadmon by 33.6% during the 3rd quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock valued at $1,083,000 after purchasing an additional 81,226 shares during the period. 51.90% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/18/kadmon-kdmn-rating-lowered-to-hold-at-zacks-investment-research.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply